Acute Myeloid Leukemia Clinical Trial
Official title:
Comparison of Ara-c 12 gm/m2 vs 18 gm/m2 Per Cycle for 3 Cycles Each as Consolidation in AML ; An Open Label Randomized Non-inferiority Study
The study will be conducted in the Department of Medical Oncology and Department of Haematology , AIIMS, Delhi. A total of 180 patients of Acute Myeloid Leukemia who are in complete remission after induction chemotherapy will be enrolled into the study and will be further randomized to the two study arms . ARM- A will receive Ara-c at 18 gm /m2 for 3 cycles and ARM -B will receive Ara-c at 12 gm/m2 for 3 cycles according to the study protocol. Aim of the study will be to compare the efficacy of the two doses in terms of the relapse free survival and overall survival as well as time to relapse and toxicity /treatment related morbidity.
Objectives
- To compare the efficacy of two different doses of Cytarabine during consolidation
therapy for newly diagnosed patients of Non APML - Acute Myeloid Leukemia who are in CR
post induction
- To compare the toxicity of the two different Cytarabine doses
Primary end point
- Relapse free survival at 1 yr from randomization
- Relapse will be defined as >5 % leukemic blasts in the marrow aspirate or new
extramedullary disease anytime after randomization
Secondary end points
- Overall survival
- Median time to relapse
- Toxicity- Haematological and Non -Haematological
Inclusion criteria
- Confirmation of Acute Myeloid Leukemia by morphologic, immunophenotypic analysis
- Suitable for HIDAC as consolidation
- AML with underlying MDS will be included
Exclusion criteria
- Previous AML chemotherapy [Hydroxyurea - not an exclusion.]
- CML-BC
- Concurrent active malignancy
- HIV infection, Uncontrolled Hepatitis B/C
- Patients being considered for upfront PBSCT (before completion of CONSOLIDATION)
- Serum Bilirubin > 2
- APML
- Delayed recovery of blood counts /persistent active infection > 45 days from start of
induction
- Patients receiving reinduction with HIDAC
- Therapy related AML Methodology
- The period of enrollment will be from July 1, 2012 to September 30 ,2013
- Baseline information will be recorded in a preformulated proforma designed for analysis
at a later date
Treatment
- Standard 3 + 7 INDUCTION with Daunomycin and Cytarabine with DNR at 60- 90 mg/m2 as per
the PS and comorbidities/active infections at presentation
- Bone marrow examination - D+ 28 of induction or earlier if needed . Patients not in CR
- reinduction regimen as per discretion of treating physician
- Patients in complete morphological remission ( after 1 or 2 inductions) : will receive
consolidation with HIDAC and will be randomized into the two study arms after written
Informed Consent: Arm A and B with 90 patients in each arm Arm A will receive HIDAC at
18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5 Arm B will receive HIDAC at
12 gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5
sample size
- Assuming a RFS of 60 % at 1 yr in each arm and keeping a non-inferiority margin of 20 %
, Alpha at 5 % ,75 patients are required in each arm on the basis of statistical
calculation.
- 15 patients added in each arm to account for losses
- Total required in each arm = 90
- ANC> 1000 , Platelet count > 1 lac required to start HIDAC
- Detailed information of the course of all the chemotherapy cycles will be recorded
including-
1. toxicity
2. details of antimicrobials
3. supportive care ( including transfusions)
4. Use of growth factors
- Cytogenetic analysis using standard technique of chromosomal banding
- Molecular analysis for mutation of FLT3-ITD will be performed
- Risk stratification will be done as per guidelines
- Patients in both arms will be kept under close follow up and will be assessed with
blood counts /PS , 2 monthly / or earlier as clinically indicated
Statistical Analysis
- Qualitative data will be analyzed using the Chi-square test
- Quantitative data will be compared by using t-test /Mann Whitney test
- Besides this survival analysis will be carried out.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |